Work

Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors

Year: 2011

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2011-4716

Authors: Lee Rosen, Patricia LoRusso, Wen Wee Ma, Johathan Goldman, Amy Weise, A. Dimitrios Colevas, Alex Adjei, Salim Yazji, Angela Shen, Stuart Johnston, Mary R. Gates, Cheryl Jones, Luna Musib, Alex De Crespigny, Iris Chan, Branimir Sikic

Institutions: The Barbara Ann Karmanos Cancer Institute, Roswell Park Comprehensive Cancer Center, Stanford University, Exelixis (United States)

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2085493719

Cites:

Cited by: 20

Related to: 10